Contrarian Sales Techniques

JANUARY 25, 2023

When I first started working as a pharmaceutical sales representative, I didn't fully understand the importance of product knowledge and accurate information. As a pharmaceutical sales representative, I have received extensive training on the products I represent.

Product Knowledge 52

Product Knowledge Pharmaceutical Sales Sales Pharmaceutical 52

Pharma Marketing Network

JULY 19, 2023

Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales. In the pharmaceutical industry, content marketing can be particularly effective for driving sales.

Marketing 98

Marketing Pharmaceutical Sales Education 98

Contrarian Sales Techniques

FEBRUARY 26, 2023

The paper was presented at the International Conference on Pharmaceutical Research and Development (IPRDC) in Kuala Lumpur, Malaysia, in June 2017. It is noteworthy that Malaysia has a pharmaceutical manufacturing sector that almost exclusively produces generic drugs, with sales revenues amounting to only 1.5%

Pharmaceutical 52

Pharmaceutical Medicine Government Side effects 52

European Pharmaceutical Review

OCTOBER 31, 2022

The Pharmacovigilance Risk Assessment Committee (PRAC) , the European Medicines Agency (EMA)’s safety board, has confirmed it recommends the withdrawal of Marketing Authorisation Application (MAA) for amfepramone obesity medicines, to prevent more patients being at risk of serious side effects. Risks of amfepramones.

Side effects 84

Side effects Medicine Safety Marketing 84

European Pharmaceutical Review

OCTOBER 9, 2023

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French.

Side effects 95

Side effects Recruitment Safety Medicine 95

European Pharmaceutical Review

NOVEMBER 16, 2023

According to Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is a genetically modified autologous CD34+ cell enriched population containing human hematopoietic stem and progenitor cells edited ex vivo by CRISPR/Cas9 at the erythroid-specific enhancer region of the BCL11A gene.

Safety 96

Safety Side effects Medicine Patients 96

Pharmaceutical Technology

JANUARY 6, 2023

While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments only slow the disease’s progression and sometimes carry risks of severe side effects, such as liver failure or the development of viral infections.

Side effects 115

Side effects Patients Marketing Safety 115

European Pharmaceutical Review

DECEMBER 22, 2023

KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.

Food and Drug Administration 95

Food and Drug Administration Side effects Safety Food 95

European Pharmaceutical Review

MARCH 25, 2024

Data supporting the positive recommendation of Emblaveo EMA’s positive recommendation for Emblaveo was based on the safety and efficacy data already available for each active substance and the results of two separate Phase III randomised studies REVISIT ( NCT03329092 ) and ASSEMBLE ( NCT03580044 ). Emblaveo was jointly developed with AbbVie.

Side effects 94

Side effects Medicine Safety Patients 94

European Pharmaceutical Review

NOVEMBER 2, 2023

The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Like Stelara, the most serious known side effect of Wezlana is infection.

Food and Drug Administration 90

Food and Drug Administration FDA Side effects Safety 90

Pharmaceutical Technology

DECEMBER 7, 2022

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

Side effects 64

Side effects Food and Drug Administration Safety Physicians 64

European Pharmaceutical Review

NOVEMBER 1, 2022

The committee advises that Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib), used for chronic inflammatory conditions, should have limited distribution to minimise risk of serious side effects such as cardiovascular diseases, blood clots, cancer and serious infections.

Side effects 89

Side effects Distribution Safety Patients 89

European Pharmaceutical Review

AUGUST 16, 2022

The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. Safety monitoring showed that the side effects observed were the same as those seen for the original Moderna booster dose and were typically mild and self-resolving. No serious safety concerns were identified.

Safety 102

Safety Side effects Medicine Healthcare 102

European Pharmaceutical Review

SEPTEMBER 20, 2022

This interchangeability refers to the fact that a reference medicine can be substituted by a biosimilar, without risk, side effects or outcomes different to the original drug. Analytical evidence by the EMA indicated that there was a lack of safety concerns regarding approval of biosimilars compared with their reference medicines.

Medicine 91

Medicine Side effects Safety Doctors 91

Pharmaceutical Technology

AUGUST 15, 2022

After the vaccine was found to meet the standards of safety and quality, the regulatory agency granted the authorisation. According to the safety monitoring, side effects were generally mild and self-resolving, as well as in line with those reported for the original Moderna booster dose. 1 Omicron variant of concern.

Side effects 85

Side effects Safety Government Pharmaceutical 85

European Pharmaceutical Review

NOVEMBER 1, 2023

The safety profile of the adapted vaccine is expected to be like that of the originally authorised Nuvaxovid, EMA said. The most common side effects with Nuvaxovid XBB.1.5 The post European approval for third adapted COVID-19 vaccine appeared first on European Pharmaceutical Review. The Comirnaty XBB.1.5-adapted

Side effects 99

Side effects Medicine Safety Marketing 99

European Pharmaceutical Review

MARCH 8, 2023

If the orally-delivered drug is confirmed have similar in safety and efficiency as the injectable forms, researchers stated that a PCSK9 inhibitor in a pill form could lower costs, increase convenience and expand patient access to the treatment. Plans for a Phase III clinical trial programme are underway.

Side effects 88

Side effects Safety Medicine Patients 88

European Pharmaceutical Review

NOVEMBER 18, 2022

The most common side effects observed were initial insomnia, irritability and dyskinesia. The efficacy and safety profile of Upstaza has been shown across clinical trials and compassionate use programmes. The post MHRA approves first gene therapy for infusion into the brain appeared first on European Pharmaceutical Review.

Side effects 126

Side effects Biopharma Safety Patients 126

European Pharmaceutical Review

APRIL 20, 2023

“These results are exciting… this treatment led to fewer days with migraine for people who had already tried up to four other types of drugs to prevent migraine and either had no improvement or had side effects that outweighed any benefits,” commented study author Dr Patricia Pozo-Rosich, PhD at Vall d’Hebron University Hospital in Barcelona, Spain.

Side effects 88

Side effects Safety Medical Pharmaceutical 88

Contrarian Sales Techniques

FEBRUARY 25, 2023

This includes potential side effects or adverse reactions to medications. Clinical studies play an essential role in determining the safety and efficacy of new drugs before they can be approved for the public. This is before a drug can be approved for public use.

Side effects 52

Side effects Medical sales reps Insurance Pharmacology 52

Pharma Leaders

JUNE 14, 2023

Eupraxia Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for EP-104IAR to treat osteoarthritis of the knee in adult patients. It offers dual advantage of providing a longer duration of pain relief, with less systemic side effects, stated the company. According to the U.S.

Food and Drug Administration 52

Food and Drug Administration FDA Side effects Food 52

European Pharmaceutical Review

JANUARY 25, 2024

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. They detail the medication’s intended use, proper administration, potential side effects and precautions. percent as EU average with some Member States as high as 25 percent).

Healthcare 84

Healthcare Healthcare Electronics Safety 84

European Pharmaceutical Review

NOVEMBER 18, 2022

A clinical trial evaluated the safety and efficacy of Tzield in 76 patients with stage 2 type 1 diabetes. The most common side effects of Tzield were identified as lowered levels of certain white blood cells, rash and headache. Tzield is administered by intravenous infusion once per day for 14 days.

Food and Drug Administration 94

Food and Drug Administration FDA Side effects Food 94

European Pharmaceutical Review

OCTOBER 18, 2022

The trial had a safety profile that was consistent with previous studies. Among the 170 axicabtagene ciloleucel-treated patients evaluable for safety, Grade ?3 The post EC approves CAR T-Cell therapy for B-cell lymphoma appeared first on European Pharmaceutical Review. Additionally, axicabtagene ciloleucel demonstrated a 2.5-fold

Side effects 102

Side effects Safety Patients Medical 102

European Pharmaceutical Review

NOVEMBER 14, 2022

CHMP’s safety update. The CHMP endorsed measures recommended by the EMA Pharmacovigilance Risk Assessment Committee (PRAC), to minimise the risk of serious side effects (cardiovascular conditions, blood clots, cancer and serious infections) of janus kinase (JAK) inhibitors for treating several chronic inflammatory disorders.

Medicine 82

Medicine Side effects Safety Pharmaceutical 82

Pharmaceutical Technology

JANUARY 27, 2023

As for Briumvi’s side effects, around 45% of patients experienced infections of the upper respiratory tract, which was 4% higher in comparison to Aubagio. Competitive pricing will therefore be essential if the drug is to compete effectively in the MS market and gain a significant patient share.

Marketing 52

Marketing Side effects Safety Specialization 52

Pharmaceutical Technology

NOVEMBER 30, 2022

While masitinib works as a multi tyrosine kinase inhibitor, tolebrutinib and fenebrutinib are both Bruton’s tyrosine kinase (BTK) inhibitors, a novel MOA that is being investigated by multiple pharmaceutical companies for both PPMS and RMS.

Patients 98

Patients Side effects Safety Pharmaceutical 98

European Pharmaceutical Review

DECEMBER 1, 2022

The approval, granted to Ferring Pharmaceuticals Inc, was given based on safety data from two randomised, double-blind, placebo-controlled studies and open-label clinical studies in the US and Canada in participants with a history of one or more CDI recurrences. diff</em> appeared first on European Pharmaceutical Review.

Food and Drug Administration 87

Food and Drug Administration Side effects Food Safety 87

European Pharmaceutical Review

DECEMBER 7, 2022

The common, expected side effects were within expectations for a vaccine in this age group. The Commission on Human Medicines (CHM), which endorsed the authorisation, advises ministers on the safety, efficacy and quality of medicinal products. Data that facilitated the line extension of Comirnaty ® for Covid-19.

Food and Drug Administration 85

Food and Drug Administration Patients Side effects Medicine 85

European Pharmaceutical Review

FEBRUARY 9, 2023

Side effects seen in the trial included headache, dizziness, constipation, and increased urine output occurred with difelikefalin. Larger clinical trials are needed to better assess the efficacy and safety of difelikefalin in notalgia paresthetica. appeared first on European Pharmaceutical Review.

Food and Drug Administration 79

Food and Drug Administration FDA Side effects Medicine 79

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Food and Drug Administration 106

Food and Drug Administration Side effects Pharmaceutical Leads 106

European Pharmaceutical Review

JULY 20, 2022

Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators. Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. Supporting regulators. It focused on data from France, Germany and the UK.

Medicine 80

Medicine Safety Side effects Electronics 80

Pharmaceutical Technology

NOVEMBER 14, 2022

The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson. In the five-patient report, mild cytokine release syndrome, a common side effect with CAR-Ts was observed, but the treatment was considered well tolerated.

Side effects 144

Side effects Patients Manufacturing Safety 144

pharmaphorum

SEPTEMBER 16, 2022

The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen.

Management 69

Management Side effects Patients Safety 69

Contrarian Sales Techniques

JANUARY 27, 2023

It can be challenging when you find yourself promoting products that seem to contradict each other, as it can raise questions about the effectiveness and safety of the products you're selling. However, it's important to understand that they work differently, have different side effects and are regulated differently.

Sales 52

Sales Side effects Education Ethics 52

Pharmaceutical Technology

JUNE 16, 2023

This includes the company’s upcoming Phase IIIb trial, but also another Phase III study and a long-term safety trial, said ANeuroTech CEO Eric Buntinx in an interview with Pharmaceutical Technology. The company has already contacted funds based in Europe and in the US, said Buntinx.

Food and Drug Administration 52

Food and Drug Administration Side effects Safety Recruitment 52

Pharmaceutical Technology

JULY 28, 2022

This pipeline includes agents such as Abivax’s obefazimod; InDex Pharmaceuticals’ cobitolimod; three interleukin-23 (IL-23) inhibitors, namely AbbVie ’s Skyrizi (risankizumab), Eli Lilly ’s mirikizumab, and Janssen’s Tremfya (guselkumab); and Takeda ’s subcutaneous formulation of Entyvio (vedolizumab) in the US.

Food and Drug Administration 98

Food and Drug Administration Safety Side effects Marketing 98